- Home
- DGX vs MRNA Comparison
DGX vs MRNA Comparison
Compare DGX & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DGX | MRNA |
|---|---|---|
| Founded | 1967 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.1B | 19.7B |
| IPO Year | 1996 | 2018 |
Fundamental Metrics
Financial Performance| Metric | DGX | MRNA |
|---|---|---|
| Price | $196.20 | $54.59 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 12 |
| Target Price | ★ $208.92 | $34.27 |
| AVG Volume (30 Days) | 706.1K | ★ 5.3M |
| Earning Date | 04-21-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | 13.78 | ★ 21.77 |
| EPS | ★ 8.75 | N/A |
| Revenue | $11,035,000,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $7.53 | $9.36 |
| Revenue Next Year | $3.77 | $15.43 |
| P/E Ratio | $22.37 | ★ N/A |
| Revenue Growth | ★ 11.78 | 4.29 |
| 52 Week Low | $164.65 | $22.28 |
| 52 Week High | $213.50 | $59.55 |
Technical Indicators
Market Signals| Indicator | DGX | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 64.69 | 54.17 |
| Support Level | $198.84 | $47.61 |
| Resistance Level | $213.35 | $54.94 |
| Average True Range (ATR) | 4.29 | 2.39 |
| MACD | 0.72 | 0.24 |
| Stochastic Oscillator | 89.85 | 66.12 |
Price Performance
Historical ComparisonAbout DGX Quest Diagnostics Incorporated
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.